WUXI BIO (02269): Total Integrated Projects Reach Record High of 945 in 2025, Bispecific/Multispecific Antibody Revenue More Than Doubles

Stock News01-12

Materials from a keynote speech delivered by WUXI BIO (02269) CEO Chen Zhisheng at the 44th J.P. Morgan Healthcare Conference revealed that the group's business maintained rapid growth in 2025. The integrated CRDMO platform added 209 new integrated projects throughout the year, with approximately half originating from the U.S. market, bringing the total number of integrated projects to a record 945. Among different molecule types, bispecific and multispecific antibodies contributed nearly 20% of the group's total revenue, representing a year-on-year increase of over 120%. With the continued execution of the "Follow and Win the Molecule" strategy, the combined number of Phase III clinical and commercial manufacturing projects reached 99, indicating potential for accelerated growth in the commercial manufacturing business. Research service business achieved record highs in both upfront and total payment amounts, with the total potential milestone payments for last year's collaborative projects exceeding $4 billion. WUXI BIO is accelerating its global footprint; after establishing a presence in China, the U.S., Ireland, Germany, and Singapore, it has now entered Qatar to serve the Middle East market. Leveraging its industry-leading digital CRDMO solutions, the company aims to deliver an exceptional customer experience and superior delivery efficiency. The aforementioned materials indicate that WUXI BIO anticipates achieving accelerated growth in 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187399747?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 15:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187399747","market":"fut","top_or_hot":-1,"title":"WUXI BIO (02269): Total Integrated Projects Reach Record High of 945 in 2025, Bispecific/Multispecific Antibody Revenue More Than Doubles","media":"Stock News","content":"<p>Materials from a keynote speech delivered by WUXI BIO (02269) CEO Chen Zhisheng at the 44th J.P. Morgan Healthcare Conference revealed that the group's business maintained rapid growth in 2025. The integrated CRDMO platform added 209 new integrated projects throughout the year, with approximately half originating from the U.S. market, bringing the total number of integrated projects to a record 945.\nAmong different molecule types, bispecific and multispecific antibodies contributed nearly 20% of the group's total revenue, representing a year-on-year increase of over 120%.\nWith the continued execution of the \"Follow and Win the Molecule\" strategy, the combined number of Phase III clinical and commercial manufacturing projects reached 99, indicating potential for accelerated growth in the commercial manufacturing business.\nResearch service business achieved record highs in both upfront and total payment amounts, with the total potential milestone payments for last year's collaborative projects exceeding $4 billion.\nWUXI BIO is accelerating its global footprint; after establishing a presence in China, the U.S., Ireland, Germany, and Singapore, it has now entered Qatar to serve the Middle East market. Leveraging its industry-leading digital CRDMO solutions, the company aims to deliver an exceptional customer experience and superior delivery efficiency.\nThe aforementioned materials indicate that WUXI BIO anticipates achieving accelerated growth in 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WUXI BIO (02269): Total Integrated Projects Reach Record High of 945 in 2025, Bispecific/Multispecific Antibody Revenue More Than Doubles</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWUXI BIO (02269): Total Integrated Projects Reach Record High of 945 in 2025, Bispecific/Multispecific Antibody Revenue More Than Doubles\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-12 15:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Materials from a keynote speech delivered by WUXI BIO (02269) CEO Chen Zhisheng at the 44th J.P. Morgan Healthcare Conference revealed that the group's business maintained rapid growth in 2025. The integrated CRDMO platform added 209 new integrated projects throughout the year, with approximately half originating from the U.S. market, bringing the total number of integrated projects to a record 945.\nAmong different molecule types, bispecific and multispecific antibodies contributed nearly 20% of the group's total revenue, representing a year-on-year increase of over 120%.\nWith the continued execution of the \"Follow and Win the Molecule\" strategy, the combined number of Phase III clinical and commercial manufacturing projects reached 99, indicating potential for accelerated growth in the commercial manufacturing business.\nResearch service business achieved record highs in both upfront and total payment amounts, with the total potential milestone payments for last year's collaborative projects exceeding $4 billion.\nWUXI BIO is accelerating its global footprint; after establishing a presence in China, the U.S., Ireland, Germany, and Singapore, it has now entered Qatar to serve the Middle East market. Leveraging its industry-leading digital CRDMO solutions, the company aims to deliver an exceptional customer experience and superior delivery efficiency.\nThe aforementioned materials indicate that WUXI BIO anticipates achieving accelerated growth in 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1720050803.USD","symbol_name":"安联全方位中国股票基金","start_time":0,"source_url":"","article_id":"1187399747","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187399747","pubTimestamp":1768204291,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Materials from a keynote speech delivered by WUXI BIO (02269) CEO Chen Zhisheng at the 44th J.P. Morgan Healthcare Conference revealed that the group's business maintained rapid growth in 2025. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1720050803.USD":"安联全方位中国股票基金","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK1589":"北水核心资产","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0181495838.USD":"施罗德新兴亚洲A Acc","02269":"药明生物","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","BK1141":"生命科学工具和服务","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","BK1576":"医药外包概念","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","BK1610":"ETF&股票定投概念","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0823426308.USD":"法巴中国股票基金","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","BK1521":"挪威政府全球养老基金持仓","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0359201612.USD":"贝莱德中国基金A2","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0051755006.USD":"摩根大通中国A (dist)","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","SG9999002463.SGD":"LionGlobal China Growth SGD"},"translate_title":"药明生物(02269)：2025年整合项目总数达945个历史新高，双特异性/多特异性抗体收入增长逾一倍","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"Materials from a keynote speech delivered by WUXI BIO (02269) CEO Chen Zhisheng at the 44th J.P. Morgan Healthcare Conference revealed that the group's business maintained rapid growth in 2025. The integrated CRDMO platform added 209 new integrated projects throughout the year, with approximately half originating from the U.S. market, bringing the total number of integrated projects to a record 945.\nAmong different molecule types, bispecific and multispecific antibodies contributed nearly 20% of the group's total revenue, representing a year-on-year increase of over 120%.\nWith the continued execution of the \"Follow and Win the Molecule\" strategy, the combined number of Phase III clinical and commercial manufacturing projects reached 99, indicating potential for accelerated growth in the commercial manufacturing business.\nResearch service business achieved record highs in both upfront and total payment amounts, with the total potential milestone payments for last year's collaborative projects exceeding $4 billion.\nWUXI BIO is accelerating its global footprint; after establishing a presence in China, the U.S., Ireland, Germany, and Singapore, it has now entered Qatar to serve the Middle East market. Leveraging its industry-leading digital CRDMO solutions, the company aims to deliver an exceptional customer experience and superior delivery efficiency.\nThe aforementioned materials indicate that WUXI BIO anticipates achieving accelerated growth in 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187399747","isCrawlerRequest":true}